Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103933 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL102248 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL199423 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL200435 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL198808 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL199832 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL100485 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL102506 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL102172 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL201458 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-4180041-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11596629-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-12-29 | — | — | US | disclosed |
| US-11325892-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3808349-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3177292-B1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-02-27 | — | — | US | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0218310-B1 | RHIZOXIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1991-03-13 | — | — | EP | disclosed |
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0353047-A2 | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4791128-A | Rhizoxin esters and salts, their pharmaceutical use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1988-12-13 | — | — | US | disclosed |
| EP-0218310-A2 | Rhizoxin derivatives, their preparation and pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-04-15 | — | — | EP | disclosed |
| CN-86102020-A | The preparation method of rhizoxin derivatives and in pharmaceutically application | — | 1986-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325892-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | LMNA 1768/4885DNM1 728/4885TSHR 415/4885 |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | LMNA 1768/4885DNM1 728/4885TSHR 415/4885 |
| US-11596629-B2 | Compounds and methods for treating cancer | SCD, SCD5, CPT1B | LMNA 2601/4885DNM1 1277/4885TSHR 1013/4885 |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | LMNA 2601/4885DNM1 1277/4885TSHR 1013/4885 |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | LMNA 2601/4885DNM1 1277/4885TSHR 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.